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Abstract
Background: Interleukin 6 (IL-6) inhibitors are the first-line treatment for idiopathic multicentric Castleman disease (iMCD);
however, there is no established treatment for cases that are resistant to IL-6 inhibitors. Although sirolimus, a mammalian target of
rapamycin inhibitor, has been suggested to be effective in patients with iMCD, the long-term safety and efficacy of sirolimus on
individuals with IL-6 inhibitor-resistant iMCD have not been evaluated.
Methods/Design: In this investigator-initiated, multicenter, open-label trial, the long-term safety of sirolimus will be evaluated in
patients participating in a placebo-controlled, randomized, double-blind, parallel-group trial on tocilizumab (TCZ)-resistant iMCD. The
study will be conducted in 7 centers in Japan. This trial will be promptly started after the evaluation and examination for 16 weeks in
the preceding study. The trial will be completed by the time the drug is approved for iMCD treatment in Japan. The primary endpoint is
the incidence of adverse events. The secondary endpoints include the following: the levels of hemoglobin, albumin, and C-reactive
protein; change in CHAP score; physician global assessment (100-mm visual analog scale); patient global assessment (100-mm
visual analog scale); and lymph node changes in subjects with lymphadenopathy.
Discussion:This clinical trial will provide evidence regarding the long-term safety of sirolimus as a potential novel therapeutic agent
for patients with tocilizumab-resistant iMCD.
Trial Registration number: jRCT2051200050
Abbreviations: CD =Castleman disease, FAS = full analysis set, IL = interleukin, ILD = interstitial lung disease, iMCD = idiopathic
Castleman disease, LAM = lymphangioleiomyomatosis, mTOR = mammalian target of rapamycin, PI3K = phosphatidylinositol-3
kinase, PPS = per-protocol set, SAS = safety analysis set, TCZ = tocilizumab, UCD = unicentric Castleman disease.
Keywords: idiopathic multicentric Castleman disease, mammalian target of rapamycin, open-label, sirolimus, tocilizumab-resistant
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Castleman disease (CD) is a lymphoproliferative disease first
described by Benjamin Castleman in 1956.[1] CD was subse-
quently classified into unicentric CD, which is a localized form
with lymph node involvement, and multicentric CD (MCD),
which is a multicentric form of the disease.[2] Lymphadenopathy
in patients with unicentric CD is localized and is generally
asymptomatic and does not show abnormalities on clinical
examination. Conversely, MCD is a systemic disease associated
with multiple lymphadenopathies and symptoms such as fever,
night sweats, weight loss, and body malaise.[3–5]
MCD can be divided into human herpes virus-8 infection-
associated MCD and idiopathic MCD (iMCD)[2]; however,
iMCD can cause organ damage and secondary amyloidosis
without appropriate treatment and can be amajor cause of death.
It reduces the quality of life and shortens life expectancy.
Interleukin 6 (IL-6) is a significant cytokine in the MCD
pathogenesis,[6] although the mechanisms underlying the IL-6
overproduction in MCD patients are not fully understood.
The presence of patients with iMCD who do not respond to
anti-IL-6 therapy suggests that pro-inflammatory cytokines other
than IL-6 also play a significant role in the iMCD pathogenesis. A
report on the efficacy of sirolimus, a mammalian target of
rapamycin (mTOR) inhibitor, in refractory iMCD[7] suggests the
phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR pathway acti-
vation in the iMCD pathogenesis. The inhibition of this pathway,
in addition to inhibiting the T and B cell proliferation that are
activated in iMCD, has a suppressive effect on vascular
endothelial growth factor, which may be particularly effective
in some IL-6-independent iMCD.
We are currently recruiting patients with iMCD who
completed a phase III, investigator-initiated, multicenter, dou-
ble-blind, randomized, parallel-group trial to confirm the long-
term safety and efficacy of sirolimus on individuals with
tocilizumab (TCZ)-resistant iMCD.[8] Herein, we describe the
final protocol (version 2.0; June 26, 2020) for this study. The
results of this study are expected to provide evidence regarding




The present study has been designed in accordance with the
Standard Protocol Items: Recommendations for Interventional
Trials and Consolidated Standards of Reporting Trials 2010
guidelines.[9,10] This is an open-label investigator-initiated,
multicenter study of the long-term safety and efficacy of sirolimus
in patients with TCZ-resistant iMCD.
This study will be conducted at 7 centers in Japan and will be
performed in accordance with the principles of the Declaration of
Helsinki[11] and the Japan Good Clinical Practice. The study was
registered to the Japan Registry of Clinical Trials as
jRCT2051200050 and was approved by the Institutional Review
Board of the Daini Osaka Police Hospital.
2.2. Participant recruitment
Participants will be recruited at the Nagasaki University
Hospital, Jikei University Hospital, Kanazawa Medical Univer-
sity Hospital, Kyoto University Hospital, Sumitomo Hospital,
Daini Osaka Police Hospital, and Kyushu University Hospital.
Based on the inclusion and exclusion criteria, all eligible
participants will be selected and approached based on informa-
tion from the electronic health record from these 7 hospitals.
Participants will be provided with an explanation regarding the
study by their treating pediatrician/rheumatologist and clinical
research coordinator and will be asked to voluntarily sign an
informed consent form before their participation.
2.3. Inclusion criteria
Patients who meet the following inclusion criteria are eligible for
this study:
1) patients who completed the 16-week treatment with an
investigational drug in the preceding trial (jRCT2071190029);
and
2) patientswho received a thorough explanation of the contents of
explanatory documents and other matters concerning clinical
trials, understood the contents thereof, and provided written
consent based on their free will to participate in this trial.
2.4. Exclusion criteria
Patients with any of the following at the time of screening will be
excluded:
1) patients with an Eastern Cooperative Oncology Group
Performance Status of 4;
2) patients who cannot use appropriate contraception during the
study drug administration period or 12 weeks after the last
treatment with the study drug;
3) female patients during lactation or pregnancy;
4) patients with complications of serious diseases that are
deemed unsuitable for the clinical trial by the investigator
or sub-investigator;
5) patients whose condition in the preceding trial is deemed
unsuitable for continued treatment by the investigator or sub-
investigator; and
6) other patients deemed inappropriate by the investigator or
sub-investigator.
2.5. Study protocol
The study is a continuation study in patients who had completed
the 16-week treatment period of the investigational drug in the
previous study. The investigator or sub-investigator then
considers whether the patient is eligible for the study, taking
into consideration the patient’s health status, severity, and
symptoms of the primary disease and complications, age, and
ability to consent. The investigator or sub-investigator explains
the consent to the subjects who are expected to complete the
preceding trial and who have completed the 12-week observation
and examination of the preceding study.
If the observation and examination at Week 0 is conducted on
the same day as the Week 16 of the preceding study, written
consent should be obtained from the subjects and others before
the initial observation and examination at Week 16 of the
preceding study. If the study does not commence on the same day
as the 16-week follow-up study, written consent should be
obtained from the subject or others within 28 days of the
completion of the 16-week follow-up study.
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The investigator or sub-investigator conducts the observation
and examination at week 0 of the trial to determine the eligibility
of the subjects based on the selection and exclusion criteria. The
overlapping items of the observation and examination at Week 0
of this study with those of the preceding 16 weeks can be
substituted. All patients who meet the inclusion criteria and do
not meet any of the exclusion criteria will receive the
investigational drug at 2 mg orally once daily. Therefore, all
participants who were assigned to the placebo group in the
preceding study will also receive the investigational drug. In
principle, the first dose of the investigational drug is administered
on the same day as the eligibility verification completion date. If
the discontinuation criteria are met, the medication is discon-
tinued, and the prescribed tests are performed. After the visit date
(i.e., the initial investigation day of the investigational drug), the
investigators will continue to administer the investigational drug
and conduct necessary examinations and surveys in accordance
with the schedule presented in Figure 1.
The planned clinical trial period is from the date of approval by
the head of the investigational site to the date of obtaining a
manufacturing and marketing approval for iMCD. The clinical
trial is terminated when it is decided to discontinue development
for this indication.
2.6. Adverse events
If an adverse event is observed in a patient during the study
period, the investigator of each medical institution should
immediately take appropriate measures and record that event
in the clinical records and case reports. The severity of adverse
events should be determined according to the Common
Terminology Criteria for Adverse Events, version 5.0. A serious
adverse event is defined as any untoward medical event that
occurs at any dose, results in death, is life-threatening, requires
inpatient hospitalization, or prolongation of existing hospitali-
zation, results in persistent or significant disability or incapacity,
or causes a congenital anomaly or birth defect.
The study design includes an independent efficacy and safety
assessment committee that will review the ongoing safety data in
an unblinded manner in accordance with the Standard Operating
Procedures for Clinical Trials, JapanMedical Association (http://
www.jmacct.med.or.jp/).
The investigational drug may increase the risk of developing
interstitial lung disease (ILD). If ILD is suspected or developed
during the study drug administration period, the investigator or
sub-investigator should examine the patient (blood pressure,
pulse rate, temperature, respiratory rate, percussion, and
auscultation, SpO2) and perform chest X-ray, CT scan, and
clinical examination to confirm the presence of ILD. If the patient
has ILD, its symptoms and severity should be confirmed, and the
drug should be withdrawn or discontinued according to the
guidelines, depending on the symptoms and severity of the ILD.
The investigator or sub-investigator should send the chest X-ray
and CT scan image data to the efficacy and safety assessment
committee and follow the standard operating procedures of the
committee.
2.7. Outcome
The primary endpoint of this study is the incidence of adverse
events. The secondary endpoints are efficacy and safety
categories.
Figure 1. Treatment schedule and outcome measures. CT = computed tomography, ECG = electrocardiogram, VAS = visual analog scale.
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2.7.1. Efficacy. We will evaluate the efficacy of the investiga-
tional drug based on the following parameters:
1) hemoglobin (g/dL): change from the baseline at 2, 4, 8, 12, and
24 weeks, every 12 weeks thereafter, and at the time of the
study completion or drug discontinuation;
2) albumin (g/dL): change from the baseline at 2, 4, 8, 12, and 24
weeks, every 12 weeks thereafter, and at the time of the study
completion or drug discontinuation;
3) C reactive protein (mg/dL): change from the baseline at 2, 4, 8,
12, and 24weeks, every 12 weeks thereafter, and at the time of
the study completion or drug discontinuation;
4) Physician Global Assessment (disease activity assessment,
100-mm visual analog scale): change from the baseline at 4, 8,
12, and 24weeks, every 12 weeks thereafter, and at the time of
the study completion or drug discontinuation;
5) Patient Global Assessment (disease activity assessment, 100-
mm visual analog scale): change from the baseline at 4, 8, 12,
and 24 weeks, every 12 weeks thereafter, and at the time of the
study completion or drug discontinuation;
6) lymph node changes in subjects with lymphadenopathy:
change from the baseline at 24 weeks, every 24 weeks
thereafter, and at the time of the study completion or drug
discontinuation as well as changes in the number of lymph
nodes >10 mm in diameter from the baseline at 24 weeks,
every 24 weeks thereafter, and at the time of the study
completion or drug discontinuation;
7) CHAP score: change from the baseline at 2, 4, 8, 12, and 24
weeks, every 12 weeks thereafter, and at the time of the study
completion or drug discontinuation; and
8) CHAP score minus C reactive protein score: change from the
baseline at 2, 4, 8, 12, and 24 weeks, every 12 weeks
thereafter, and at the time of the study completion or drug
discontinuation.
2.7.2. Safety. The safety evaluation indices of this clinical trial
are as follows:
1) adverse events, including the incidence rates of adverse events,
serious adverse events, and side effects;
2) laboratory tests, including hematological examination, blood
biochemical examination, and urinalysis; and
3) all medically significant indicators, including physical find-
ings, vital signs, imaging tests, electrocardiogram results,
echocardiographic findings, etc.
2.8. Data collection and management
The investigators will be provided access to an online, web-based,
electronic data capture system. Only the investigator will be able
to enter and modify data in the electronic case report form. All
study findings and documents will be regarded as confidential.
Patients will be identified on the electronic case report form by
their patient number, but not by name. Document confidentiality
must be maintained by the investigator to ensure the anonymity
of the participants.
During the study, a sponsor-investigator will perform regular
site visits to review protocol compliance, conduct source data
verification, assess drug accountability and management, assess
laboratory procedures, and ensure that the study is being
conducted according to pertinent regulatory and protocol
requirements. The sponsor-investigator controls the trial quality
in accordance with the protocol, each standard operating
procedure, and the trial monitoring/audit protocol. The primary
operations are as follows:
1) hold and explain the protocol to the investigator or trial
collaborators upon trial initiation or as necessary to ensure an
accurate protocol understanding and judgment and evalua-
tion standardization;
2) subject eligibility will be automatically checked by an
electronic data capture system to eliminate selection and
exclusion violations;
3) the monitor should visit the institution on a regular basis to
ensure that the protocol and good clinical practices are
followed to ensure proper conduct of the trial and to confirm
data accuracy;
4) records and reports concerning the operation of clinical trials,
data collection, data management, statistical analysis, and
adverse event analysis shall be performed in accordance with
standard operating procedures, and inspections and con-
firmations shall be made;
5) to ensure that the clinical trial is properly conducted, the
sponsor-investigator will confirm the quality of each develop-
ment activity through quality control. Auditors independent
from departments involved in the drug development and
implementation will systematically investigate and confirm
clinical trial operations and documents in accordance with
standard operating procedures for the implementation of
audits; and
6) all source documents will be made available for review at the
request of the sponsor-investigator or national or internation-
al regulatory authority.
2.9. Statistical analysis
The details of the statistical analysis will be documented in the
statistical analysis plan. The statistical analysis planwill be signed
off prior to the unblinding of the preceding double-blind study.[8]
Safety analysis set (SAS) will consist of all subjects who will have
received at least 1 dose of the study drug in the present study. Full
analysis set (FAS) will consist of the SAS subset who will have
been administrated the study drug at least once in the present
study and who will have result measuring at least one of the
efficacy endpoints after the first administration of the investiga-
tional drug. Modified FAS (mFAS) will consist of the FAS subset
that will have never changed the TCZ dose amount from the
randomization in the preceding double-blind study[8] to the end
of the observation of the subject. Per-protocol set (PPS) will
consist of the FAS subset excluding those with major deviations
from the protocol of the present study. In the PPS analyses, the
subjects who will have received the treatment of the opposite
treatment group, against the allocation at the randomization in
the preceding double-blind study,[8] will be included in the
opposite treatment group against the allocation at the randomi-
zation. We will perform statistical analyses for the primary
endpoint using SAS and for the secondary endpoints using FAS,
modified FAS, and PPS.
As a primary analysis, safety evaluation summaries will be
presented as cross-tables of adverse events by the treatment
group, causality and severity will be created; in a secondary
analysis, the period of the adverse event onset will be included in
the cross-tabulation factors. The event names will be defined by
the system organ classes and preferred terms in the Medical
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Dictionary for Regulatory Activities terminology. The time-series
fluctuation of the numerical measuring results from each patient
will be plotted for each safety endpoint. Moreover, we will
calculate summary statistics for each endpoint at each time point.
As for the measuring results of the outcomes listed in the
section 2.7, variation through the observation period will be
estimated by a mixed-effect model with random intercepts of
subjects.
3. Discussion
Treatment with sirolimus achieved clinical remission in IL-6
inhibitor-resistant iMCD cases, suggesting an increased PI3K/
Akt/mTOR pathway activity in iMCD patients[7,12,13]. To
confirm these observations, we designed the “a randomized,
double-blind, placebo-controlled, parallel-group trial of siroli-
mus for TCZ-resistant idiopathic multicentric CD” as a
preceding study.[8] This open-label extension study aimed to
evaluate the long-term safety and efficacy of sirolimus in patients
who completed the preceding study.
Sirolimus has already been approved for lymphangioleiomyo-
matosis (LAM) treatment in Japan in 2014, and the long-term
safety profile of sirolimus has been previously shown.[14] In
addition, sirolimus has been approved by the Food and Drug
Administration to prevent acute rejection in kidney transplanta-
tion for 20 years, and the evidences on its long-term safety are
accumulating.[15,16] These data demonstrate the long-term safety
of using sirolimus in LAM and post-renal transplant patients in
the real-world clinical practice. However, iMCD patients are
more likely to receive concomitant immunosuppressive agents,
such as TCZ and glucocorticoids, than patients with LAM.
Furthermore, sirolimus is susceptible to CYP3A4 inhibitors and
inducers, and the different concomitant medications used may
result in different toxicities compared with LAM. In this study,
we will determine whether the effects of sirolimus are attenuated
by long-term administration, in addition to its tolerability to the
long-term administration.
This trial will evaluate the long-term safety and efficacy of
sirolimus in patients with TCZ-resistant iMCD. It will contribute
to the identification of the effects of long-term sirolimus use in
organ damage associated with chronic inflammation. These
findings may support the evidence of mTOR-targeted therapy in
patients with severe iMCD.
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